NeoGenomics Balance Sheet Health
Financial Health criteria checks 4/6
NeoGenomics has a total shareholder equity of $923.4M and total debt of $538.9M, which brings its debt-to-equity ratio to 58.4%. Its total assets and total liabilities are $1.6B and $716.9M respectively.
Key information
58.4%
Debt to equity ratio
US$538.92m
Debt
Interest coverage ratio | n/a |
Cash | US$384.83m |
Equity | US$923.41m |
Total liabilities | US$716.93m |
Total assets | US$1.64b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NG9's short term assets ($573.9M) exceed its short term liabilities ($76.7M).
Long Term Liabilities: NG9's short term assets ($573.9M) do not cover its long term liabilities ($640.2M).
Debt to Equity History and Analysis
Debt Level: NG9's net debt to equity ratio (16.7%) is considered satisfactory.
Reducing Debt: NG9's debt to equity ratio has increased from 30.9% to 58.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NG9 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: NG9 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 43.6% each year